

# PROCUREMENT APPEALS

5

1

2

3

4

6

7

IN THE APPEAL OF,

JMI MEDICAL SYSTEMS INC.

Appellant.

8

10

11

12

13 14

15

16 17

18

19

20

22

23

2425

26

27

28

APPEAL NO: <u>OPA-PA-07-011</u>

FINDING AND RECOMMENDATIONS OF HEARING OFFICER

# I. INTRODUCTION

This is the Finding of the Hearing Officer, ROBERT G.P. CRUZ, ESQ. on a procurement appeal filed on December 12, 2007, by JMI Medical Systems, Inc., (hereafter "JMI") regarding the Guam Memorial Hospital Authority's (hereafter "GMHA") solicitation for a Microbiology Analyzer. Pre-Hearings were held on five separate dates as issues relating to discovery required resolution before the formal Hearing could be scheduled. Present and making arguments on behalf of their clients at the Pre-Hearings were John S. Unpingco, Esq., of the Law of Offices of John S. Unpingco & Associates LLC, representing GMHA, and Benjamin C. Sison, Esq., of Sison, P.C., representing JMI.

A Hearing on this procurement appeal was held on October 30, 2008. At Hearing JMI was represented by Mr. George Neil P. Valdes, Esq. of Sison, P.C. and GMHA was represented

1 Prehearings were held on February 6, March 27, May 15, June 20, and September 4, 2008, to attempt settlement and agree on

witness lists, exhibits, subpoenas and deposition dates.

# Finding of Hearing Officer - 1

by Georgette Bello Concepcion, Esq., of the Law Offices of John S. Unpincgo & Associates LLC. Witnesses subpoenaed to testify at request of the parties were Glenda Pangelinan, GMHA Laboratory Assistant Administrator, William Kando, GMHA Chief Planner, and John Benavente, GMHA Medical Electronic Superintendent and Jean Grape Ko, Sales Manager for JMI.

A Motion for Summary Judgment was filed by the Appellant on October 17, 2008, and opposed by GMHA on October 24, 2008. This Motion was denied in a written decision on October 30, 2008, on the basis that genuine issues of material fact were in dispute.

In this matter, the Hearing Officer recommends that the Public Auditor hold that GMHA's selection of Medpharm was proper as they were responsive to the bid, but the procurement of two Microbiology Analyzers, while under appeal, was improper. Accordingly, the Hearing Officer recommends that the Public Auditor affirm the procurement of one Microbiology Analyzer in the best interest of the territory, but overturn the procurement from Medpharm of a second, unannounced and non-competitively procured, analyzer.

#### II. FINDINGS OF FACT

These findings are based on the Procurement Record, all documents submitted by the parties in the appeal, as well as all testimony and arguments presented at the October 30, 2008, Hearing in this matter.

Based on the record in this matter, the Hearing Officer recommends that the Public Auditor make the following findings of fact:

- 1. Bid Invitation No. GMHA Bid 024-2007(IFB) was issued on June 22, 2007.
- 2. Three bids were timely received in response to the IFB by July 12, 2008 by:
  - a. Medpharm Corporation (Medpharm)

1	b. JC Marketing, Inc. (JCM)
2	c. JMI
3	3. At opening, GMHA recorded the following price bids:
4	a. Medpharm
5	
6 7	1. \$79,238 for Option 1, "Vitek 2 Compact 60 analyzer with Observa
8	system software" to include installation, training, kit startup and
9	other accessories
10	2. \$69,528 for Option 2, "Vitek 2 Compact 60 analyzer without
11	Observa system software" to include installation, training, kit
12	startup and other accessories
13	b. JCM
14	1. \$128,450 for a "Becton-Dickinson Phoenix 448100" analyzer
15	(\$90,200) to include installation, training and test panels (\$38,250)
16 17	c. JMI
18	
19	1. \$145,900 for Option 1, "Vitek 60 System" analyzer (\$64,665) to
20	include 300 test kits/panels (\$67,635), and technical support,
21	training, and installation (\$13,600)
22	2. \$189,950 for Option 2, "Vitek 2 Compact 60 Configuration"
23	analyzer (\$98,590) to include 300 test kits/panels (\$77,760) and
24	technical support, training, and installation (\$13,600)
25	
26	
27	
8	

- 4. GMHA found JCM non-responsive as the required non-collusion affidavit was not submitted<sup>2</sup> as part of the bid package. Both Medpharm and JMI were deemed responsive.
- 5. On August 10, 2007, GMHA sent letters to Medpharm and JMI requesting additional cost information for three specific types of reagents cards.
  - 6. JMI and Medpharm both submitted the requested cost information to GHMA as follows:

### a. Gram Positive Susceptibility Test Cards

### **AST-GP63 (22101)**

Medpharm:

\$92.51

JMI:

\$259.20 / Bx.

#### **AST-GP66 (22175)**

Medpharm:

\$92.51

JMI:

\$259.20 / Bx.

### b. Gram Negative Susceptibility Test Cards

### **AST-GN20 (22184)**

Medpharm:

\$92.51

JMI:

\$259.20 / Bx.

#### AST-GN07 (22006)

Medpharm:

\$92.51

JMI:

\$259.20 / Bx.

# c. Streptococcus Pneumoniae Susceptibility Test Cards

\$259.20 / Bx.

## <u>AST-GP65 (22149)</u>

Medpharm:

\$92.51

JMI:

<sup>2</sup> JMI Notice of Appeal pg. 2

28

- 7. In an August 14, 2007, recommendation letter from the Lab Assistant Administrator to the GMHA Hospital Administrator it was indicated that "the competitive pricing offered by Medpharm makes it possible for [GMHA] to purchase two instruments.' (August 14, 2007 letter from Glenda Pangelinan to PeterJohn D. Camacho)
- 8. On August 17, 2007, a decision was made by GMHA to award Medpharm a contract for the purchase of two "Vitek 2 Compact 60's with Observa software" Microbiology Analyzers, as they were the lowest priced bidder.
- 9. On August 31, 2007, JMI issued a protest letter to GMHA regarding the award to Medpharm. The basis of the protest was that Medpharm's bid was non-responsive. Specifically, that MedPharm did not include the cost of reagents and test supplies in its initial bid submission in contravention of GMHA 024-2007 IFB requirements under the "all or none" provision expressly provided for in the IFB.
- 10. On September 11, 2007, GMHA responded to JMI's protest and concluded that the "protest was without merit and should not be sustained." JMI submitted a September 13, 2007, letter in response offering additional information for reconsideration on GMHA's September 11 decision.
- 11. In response to JMI's September 13, 2007, letter for reconsideration and their initial August 31, 2007, letter of protest GMHA issued a November 27, 2007, decision on the protest reaffirming the Hospital's award to Medpharm for the procurement of an automated microbiology analyzer. The November 27 decision also indicated that "the [price] bids for [the] reagent supplies [were] all rejected." Only the award of the equipment was to be made.

12. On November 28, 2007, GMHA issued Purchase Order No. 28000864 to Medpharm for one (1) Vitek 2 Analyzer, charging a FY-05 NBHPP-HRSA<sup>3</sup> grant. The purchase covered installation, validation and training of two technicians and one biomedical personnel.

- 13. On the same day GMHA also issued Purchase Order No. 28000865 to Medpharm for one (1) Vitek 2 Analyzer, as an "additional order" to PO 28000864, also charging the FY-05 NBHPP-HRSA grant.
- 14. On December 12, 2007, JMI filed this appeal with OPA fifteen days following GMHA's November 27, 2007, decision on the protest.

#### III. ANALYSIS

This case involves GMHA's solicitation for bids for a Microbiology Analyzer to replace GMHA's current equipment.

### A. Responsiveness of Bids

At issue is whether Medpharm's bid was or was not responsive to the GMHA IFB and whether GMHA should have rejected MedPharm's bid and selected JMI's offer instead. JMI's position is that Medpharm itself was non-responsive and should have been eliminated from competition.

A responsive bidder is defined in Guam statutes at 5 G.C.A. Section 5201(g) as, "a person who has submitted a bid which conforms in all material respects to the Invitation for Bids". JMI submitted a bid for the required equipment and reagents and test supplies, claiming that the IFB required both as part of its "all or none" participation. In GMHA's September 11, 2007, letter to JMI in response to the protest GMHA explained that the "intent of the solicitation

<sup>&</sup>lt;sup>3</sup> National Bioterrorism Hospital Preparedness Program - Health Resources and Services Administration

25

26

27

28

was only to procure an Automated Microbiology Analyzer to replace its current equipment." GMHA Laboratory Assistant Administrator, Glenda Pangelinan, further testified during the Hearing, that the reference within the scope of services to "provide reagents and supplies for a minimum of 3,000 tests per year for use with Microbiology Analyzer" was only to ensure that the successful bidder was able to provide reagent supplies for the analyzer being offered. This testimony reaffirmed Ms. Pangelinan's statements made in a September 6, 2007, Memorandum to the GMHA Supply Management Administrator in response to the filed protest, where she wrote that no cost request or requirement was made in the initial IFB on the reagents and supplies themselves. Based on the testimony received from Hearing and the record presented before her, the Public Auditor has determined that Medpharm was responsive to the IFB since the initial bid had no requirement to provide a cost or price bid for reagents and supplies. Medpharm firmly responded with the lowest priced analyzer at \$79,238 for a "Vitek 2 Compact 60 analyzer with Observa system software" with installation and training included. Medpharm's submitted proposal fulfilled the scope of services requested by the IFB regarding the equipment, installation/ validation, technical support, and training of the IFB.

Only in their August 10, 2007, letter request to JMI and Medpharm did GMHA request price quotations for specific reagent cards from Medpharm and JMI. GMHA stated that the request was necessary as it did not state what reagents and supplies were to be obtained in the initial IFB. This information was requested after bid opening but prior to completing the selection evaluation. The Hearing Officer recommends that the Public Auditor has determine that August 10 request for price quotations had no effect on the initial award to Medpharm for the purchase of the Vitek 2 Compact 60 Analyzer as Medpharm was also the lower priced bidder on the reagents and supplies in comparison to JMI.

## B. Halting of Procurement During Pendency of Appeal with OPA

Normally, a timely appeal would result in the government agency halting further action on the procurement pending a determination by the Public Auditor or Superior Court that the procurement was in order. 5 G.C.A. Chapter 5 Section 5425 (g) states:

In the event of a timely protest under Subsection (a) of this Section or under Subsection (a) of Section 5480 of this Chapter, the Territory shall not proceed further with the solicitation or with the award of the contract prior to final resolution of such protest, and any such further action is void, unless:

- (1) The Chief Procurement Officer or the Director of Public Works after consultation with and written concurrence of the head of the using or purchasing agency and the Attorney General or designated Deputy Attorney General, makes a written determination that the award of the contract without delay is necessary to protect substantial interests of the Territory; and
- (2) Absent a declaration of emergency by the Governor, the protestant has been given at least two (2) days notice (exclusive of territorial holidays); and
- (3) If the protest is pending before the Public Auditor or the Court, the Public Auditor or Court has confirmed such determination, or if no such protest is pending, no protest to the Public Auditor of such determination is filed prior to expiration of the two (2) day period specified in Item (2) of Subsection (g) of this Section.

However, during the hearing OPA learned that, after the procurement appeal began, GMHA continued with the award and purchase of the Microbiology Analyzer that was the object

2.4

of the protest, and also bought a second one, under the same procurement.<sup>4</sup> While under appeal, making any purchase without the written determination of the Attorney General or designated Deputy Attorney General is a clear violation of procurement law and procedure under Chapter 5 Section 5425(g). Despite a violation, the Public Auditor may affirm a procurement, if it is in the best interests of the Territory. In this case, the Hearing Officer recommends that the Public Auditor affirm the procurement of **one** Analyzer in the best interests of the Territory given the fact that federal funds used to purchase the equipment may have expired and been lost.

# C. Objection to Discussion of Quantity Purchased by GMHA Counsel

At the formal hearing, GMHA's counsel objected to Appellant's attorney raising the issue that GMHA purchased a second analyzer, which was not revealed in the initial procurement protest submitted by JMI. OPA has the authority to determine procurements de novo based upon testimony presented during the appeal process. 5 G.C.A. Section 5703. If GMHA concealed the purchase of a second analyzer using the same procurement, the Public Auditor may, sua sponte, review the matter.

With regard to the appropriate remedy, the Public Auditor is guided by 5 G.C.A. Section 5703 stating that the Public Auditor's jurisdiction shall be utilized to promote the integrity of the procurement process and the purposes of Chapter 5. The Model Procurement Act requires the appropriate Policy Office to promulgate rules relating to variations in quantity, among other topics. The Guam Procurement Code is silent with regard to variations in quantity. However, the Procurement Regulations, at 2 GAR DIV. 4, do address the issue of quantity in the issuance of Definite and Indefinite Quantity Contracts. They are mirrored in GMHA's Procurement

<sup>&</sup>lt;sup>4</sup> Testimony and letter of Glenda Pangelinan.

Regulations in sections 6-101.05.1 and 6-101.05.2. Thus, we are posed with the question as to whether a doubling of the purchase from one to two items was reasonable and necessary. Normally when quantity is uncertain, the IFB will indicate this fact, or request bids on a base quantity and have an option for additional quantities. Formation of Government Contracts, Cibinic and Nash, The George Washington University, 3<sup>rd</sup> Edition. In this instance, the procurement was for a definite quantity of **one** Microbiology Analyzer.

It is patently unfair to potential suppliers for a change in the quantity of equipment procured when the quantity advertised and the quantity actually purchased increases by 100 per cent from the time of advertising to moment of the actual purchase. Although the instant procurement is for a definite quantity, which permits a 10 per cent (10%) increase, a doubling of the purchase remains a violation of the principle regarding definite versus indefinite quantity procurements.

## D. Procurement Using the Invitation for Bids was Flawed

The procurement solicitation form issued by GMHA was also flawed as GMHA incorrectly allowed the bids to be evaluated like proposals under a Request for Proposal (RFP) solicitation, which can be distinguished from an IFB. In Fleet Services, Inc. vs. Department of Administration, Government of Guam, 2006 Guam 6, the Supreme Court of Guam distinguished between competitive sealed bids and the limited exceptions allowed for deviation from determining winning bidders due to price. In Fleet Services, at pertinent part, the Guam Supreme Court stated:

We hold that the Request for Proposal DOA RFP-03-001 to procure the operation, management and maintenance of the Guam Mass Transit system, violated the Guam Procurement Code. Title 5 G.C.A. Section 5210 mandates that government

contracts in the Executive Branch be awarded using the competitive sealed bidding process, subject to limited statutory exceptions. The procurement in this case did not fall within any of the exceptions; specifically, it was not a procurement for professional services as contemplated by 5 G.C.A. Section 5121. Here, as in Fleet Services, there was no procurement of professional services involved. Thus, the focus should have been on awarding the bid to the lowest bidder responding to the IFB. Price negotiations are conducted for an RFP rather than an IFB where the lowest priced bidder receives the award so long as specifications are met.

No. 25 of the "Sealed Bid Instructions" titled "Award, Cancellation, and Rejection" indicate that the "award shall be made to the lowest responsible and responsive bidder, whose bid is determined to be the most advantageous to GMHA and the Government, taking into consideration the evaluation factors set forth in this solicitation. However, under the IFB's "Bid Specifications Section VII Proposal Evaluation and Award of Contract" it states in conflict that:

The selection committee will evaluate all proposals and select the top three companies. The top three company proposals will be forwarded to the Hospital administrator for final selection of the **most qualified company**. (**emphasis added**). Interviews with the company may be conducted during the evaluation period. GMHA will negotiate a contract with the selected company for the required services if compensation, contract requirements and contract documents can be agreed upon with the selected company.

Under this Specifications Section VII of the IFB it appears that when an evaluation takes place, the highest ranked and most qualified bidder will be awarded the bid, so long as they meet all the qualifications, but not necessary the lowest bidder. This procedure is not appropriate for an IFB

and should not be used. Local procurement law is clear that negotiations are conducted for RFP's not IFB's, where the procurement of professional services are involved. In an IFB the lowest priced responsible bidder receives the award so long as specifications are met. In this instance, GMHA was correct to issue the contract to the lowest priced and responsible bidder, but any negotiations that took place would have been improper.

### E. Appropriate Remedies

The Procurement Law and GMHA Procurement Regulations Section 9-203.1 relate to Remedies After an Award. It states: if after an award it is determined that a solicitation or award of a contract is in violation of law, then:

- 1. If the person awarded the contract has not acted fraudulently or in bad faith:
  - (a) the contract may be ratified and affirmed, provided it is determined that doing so is in the best interests of the Hospital; or
  - (b) the contract may be terminated and the person awarded the contract shall be compensated for the actual expenses reasonably incurred under the contract, plus a reasonable profit, prior to the termination;
- 2. If the person awarded the contract has acted fraudulently or in bad faith:
  - (a) the contract may be declared null and void; or
  - (b) the contract may be ratified and affirmed if such action is in the best interests of the Hospital, without prejudice to the Hospital's rights to such damages as may be appropriate.

There is no evidence in the instant case of bad faith or fraud by Medpharm. Thus, the following GMHA rules would control: 9-203.01.1 No Fraud or Bad Faith by Contractor and 9-203.01.2 General, which states:

Upon finding after award that a Hospital employee has made an unauthorized award of a contract or that a solicitation or contract award is otherwise in violation of law where there is no finding of fraud or bad faith, the Hospital Administrative may ratify or affirm the contract or terminate it in accordance with this Section after consultation with the Attorney General.

In this procurement no evidence was presented that GMHA consulted with the Attorney General to seek ratification of the contract as in the best interests of the Territory. No evidence was provided that the U.S. Department of Health and Human Services (HHS) approved the doubling of the order for a second analyzer, although Mr. Kando of GMHA testified that it was a common practice for GMHA to receive approval from HHS for variances in quantity in the procurement process.

Although no evidence was presented at the hearing that showed that GMHA sought confirmation of the procurement we conclude that the Hospital Administrator did approve it.

#### IV. CONCLUSION

Based on the foregoing, the Hearing Officer recommends that the Public Auditor determine that although Medpharm and JMI were responsive to GMHA's IFB, JMI was not the lowest bidder. The Hearing Officer further recommends that the Public Auditor find that JMI's bid was higher for both the equipment and the supplies and reagents; therefore, GMHA was not in error in rejecting JMI's bid and awarding the contract for one analyzer to Medpharm. GMHA did not stay the procurement after an appeal was timely filed, in violation of 5 G.C.A. 5425(g). GMHA also purchased **not one**, **but two**, Microbiology Analyzers from Medpharm after publicizing to all prospective bidders that only one analyzer would be purchased. However, given the fact that federal funds were used to purchase the equipment and may have been lost,

the Hearing Officer recommends that the Public Auditor affirm GMHA's action on the purchase of one Vitek 2 Analyzer. As the second analyzer was procured without announcement or full competition, the Hearing Officer recommends the Public Auditor overturn the awarding of the second Vitek 2 Microbiology Analyzer (which remains at Medpharm in storage according to testimony of Glenda Pangelinan). The purchase of the second analyzer should be procured using the Competitive Sealed Bidding procedures required by 5 G.C.A. Section 5211. As the Hearing Officer recommend that the Public Auditor find that JMI should not have been awarded the contract, the Hearing Officer further recommends that the Public Auditor deny JMI's request for lost profits and costs of filing the appeal.

A copy of this Finding of Hearing Officer shall be provided to the parties and their respective attorneys, in accordance with 5 G.C.A. Section 5702, and shall be made available for review on the OPA Website <a href="https://www.guamopa.org">www.guamopa.org</a>.

**DATED** this 16<sup>th</sup> day of January, 2009.

ROBERT G.P. CRUZ, ESQ.

Hearing Officer